Partner Headlines - BMY

  1. Bristol Myers Reports Data Supporting Clinical Development Of ...

    Benzinga
  2. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD
  3. Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

    Benzinga
  4. Lannett Joins Big-Game Hunt For Drugmaker Acquisitions

    IBD
  5. Bristol-Myers goes for the gut

    IBD
  6. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  7. Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals ...

    GuruFocus
  8. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  9. Morning Market Gainers

    Benzinga
  10. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  11. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  12. Strong Dollar Weakens Views

    IBD
  13. Drugmakers Warn On Dollar

    IBD
  14. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  15. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  16. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  17. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  18. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  19. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  20. Earnings Scheduled For January 27, 2015

    Benzinga
  21. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus
  22. 3 High-Flying Health Care Stock IPOs To Watch In 2015

    IBD
  23. BRISTOL-MYERS SQUIBB

    IBD
  24. Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

    Benzinga
  25. Feeling Good With This Med Company

    GuruFocus
  26. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  27. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  28. Celgene Outlook Is Upbeat

    IBD
  29. Celgene, Bristol-Myers Cancer Drug News Lifts Stocks

    IBD
  30. Bristol-Myers Hits 14-Year High On Cancer Drug Trial

    IBD
  31. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  32. Morning Market Gainers

    Benzinga
  33. Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2 ...

    Benzinga
  34. What Investors Should Expect From Portola Pharmaceutical's Upcoming ...

    Benzinga
  35. Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight ...

    Benzinga
  36. Bristol-Myers Squibb and California Institute for Biomedical ...

    Benzinga
  37. 5 Biotech Stocks With Big News Due In January

    IBD
  38. FDA's OKs may prescribe hits

    IBD
  39. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  40. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  41. Celgene drug could gain share

    IBD
  42. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  43. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  44. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
  45. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus
  46. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus
  47. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD
  48. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers ...

    GuruFocus
  49. Screening Pharma Stocks Amid Turnaround

    YCharts
  50. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  51. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  52. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  53. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  54. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  55. Lung cancer drug promising

    IBD
  56. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  57. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  58. Eliquis revives Bristol-Myers

    IBD
  59. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  60. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  61. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  62. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  63. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  64. Earnings Scheduled For October 24, 2014

    Benzinga
  65. Must Watch Stocks for Today

    Benzinga
  66. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  67. Drug ETFs Attractive Buys On Pullback

    Benzinga
  68. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  69. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  70. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  71. The Six Types of Winning Stocks

    GuruFocus
  72. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  73. Merck to release hep C data

    IBD
  74. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  75. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  76. Bristol-Myers pulls FDA filing

    IBD
  77. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  78. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  79. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  80. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  81. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  82. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  83. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  84. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  85. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  86. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  87. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  88. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  89. Bristol-Myers Drug Gets OK

    IBD
  90. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  91. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  92. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  93. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  94. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  95. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  96. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  97. Drugmaker AstraZeneca Returns To Growth

    IBD
  98. The Stocks Already in Correction Mode

    FoxBusiness
  99. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  100. Bristol-Myers surprises Street

    IBD
Trading Center